Galderma Reports Results from the P-III (READY-3) Study of RelabotulinumtoxinA for Treating Frown Lines and Crow’s Feet
Shots:
- The P-III (READY-3) study aims at finding the safety and efficacy of RelabotulinumtoxinA vs PBO for treating moderate to severe frown lines or crow’s feet, either as a single/simultaneous treatment
- The results showed improvement in frown lines (71%) or crow’s feet (45%) with single/simultaneous treatment. Investigator-reported response rates include 94-96% reporting none/mild frown lines and 79-84% reporting none/mild crow’s feet. Median time to return to baseline severity was ~6mos. 91% were satisfied with simultaneous treatment at 1mos.
- The above results support the data from (READY-1 and READY-2) studies which revealed RelabotulinumtoxinA’s rapid onset of action on D1 for frown lines (39%) and crow’s feet (34%) and had an effect for 6mos.
Ref: Galderma | Image: Galderma
Related News:- Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
